SBIR/STTR Research Award

A new approach to solvent determination in QM/MM-based X-ray crystallographic refinement

Award identifier b6ce5f9f92fe816f5a5cc70ff4db63e97eba2d662113f2290b0491faf28870f8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$141,089

Program and phase

SBIR · Phase I

Award year

2015

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
QUANTUMBIO INC
Proposal award date
2014-12-01
Contract end date
2016-05-31
UEI
SFCDUHJNHBM4
Solicitation number
PA14-071
Topic code
100

Research abstract

DESCRIPTION provided by applicant Success in structure based drug design SBDD and fragment based drug design are ultimately largely dependent upon the quality of the three dimensional D structure of protein ligand and protein protein complexes that is the core structural technique Both nuclear magnetic resonance NMR and X ray crystallography are used to determine experimental models pertaining to these structures Through a previous project QuantumBio Inc improved the quality of the X ray refinement through integration of the Companyandapos s quantum mechanics QM based DivCon Discovery Suite with the PHENIX crystallographic package This natural synergy brings the power and accuracy of quantum mechanics to the field of X ray refinement as it plays to the core strengths of QM methods e g no atom types support for more andquot exoticandquot chemical systems metals and so on This early success has led to an expanded commercial offering that was released in February The present proposal is focused on a further improvement the accuracy of the X ray refinement protocol by incorporating improved explicit solvent structure determination It is quite clear an there is a growing body of evidence that indicates that the influences of solvent have significant impact on the ligand and receptor structure as well as on the energetics of the binding Very often exploration of an active site such as in lead discovery and optimization is a question of whether or not additional andquot unseenandquot waters are mediating the interactions between ligand protein cofactor and so on An intrinsic problem in macromolecular X ray crystallography is that only a partial number of solvent molecules can be unambiguously revealed due to the resolution limitations Unlike approaches such as WaterMap conventional D RISM and SZMAP which are used to predict waters regardless of their agreement with experiment the key innovation of this method is through the use of an advanced explicit water determination algorithm to filter crystallographic data and generate the complete experimental solvent structure within the macromolecular complex In preliminary studies performed with our partners the evidence that this approach is applicable to the problem at hand is quite compelling Specifically the results for the A lysozyme crystal structure EPE have shown that the application of the new solvation methodology leads to twice as many waters or a improvement in the hydration shell for the low resolution lysozyme structure accompanied by the improvement of the overall crystallographic statistics The method also successfully found key crystallographic andquot bridgingandquot waters along with active site pocket stabilization waters when executed on the protein ligand complex represented in PDBid ERQ Together these preliminary results are quite encouraging and completion of this SBIR will allow us to completely generalize and validate the method and prepare it for commercial deployment PUBLIC HEALTH RELEVANCE The successful completion of the SBIR grant will have a major impact on improving human health It will improve the quality of protein structures facilitate the understanding of biomolecular dynamics and will provide higher quality structural insights into protein ligand drug interactions which will enhance our ability to rationally desig novel therapeutics for human diseases The research will yield software package and refinement service available to the pharmaceutical industry for the determination of improved X ray models

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

19 SBIR/STTR records share this UEI (2005–2025). Reported award amounts total $9,699,824. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.